-
Group Revenue Growth: 6% in constant currencies.
-
Underlying EBITDA Growth: 12% year-over-year.
-
Underlying EBITDA Margin: Close to 30%.
-
Bioprocessing Solutions Sales Revenue Growth: Nearly 9% year-over-year in constant currency.
-
Lab Products & Services Sales Revenue Decline: 4% in constant currency.
-
Sales Revenue: EUR 1.767 billion, up 6.1% in constant currencies and 5.2% in reported currency.
-
Order Intake: Grew more than sales, with a 12-month rolling number above one.
-
Underlying EBITDA: EUR 527 million, up 11.9%.
-
Regional Performance: Strongest growth in the Americas.
-
Free Cash Flow: EUR 122 million, up EUR 14 million.
-
Net Debt to Underlying EBITDA Ratio: Improved from 4.0 times to 3.8 times.
-
CapEx Ratio: 9.1% of sales in H1, expected to be around 12.5% for the full year.
-
Equity Ratio: 37.8%.
Release Date: July 22, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
-
Sartorius AG (SARTF) reported a 6% growth in group revenue in constant currencies, driven by strong growth in consumables.
-
The underlying EBITDA increased by 12% year-over-year, with a margin close to 30%, indicating significant margin expansion.
-
Bioprocessing solutions sales revenue grew by nearly 9% year-over-year on a constant currency basis, driven by the growth in consumer business.
-
The company launched several new products to enhance efficiency and productivity in drug development and manufacturing processes.
-
Sartorius AG (SARTF) confirmed its full-year 2025 guidance, reflecting confidence in its business performance and order pipeline.
-
The Equipment business remained soft, with continued hesitation around larger capital investments by customers.
-
Sales revenue in the Lab Products & Services division declined by 4% in constant currency due to a challenging market situation.
-
The company faces potential tariff impacts, with expected effects to increase over the second half of the year.
-
There is a higher level of ambition and leeway required for the Lab Products & Services division to meet its guidance.
-
The company is operating in a 10% blanket tariff environment, which could lead to a 1-percentage-point impact on sales and a potential dilution effect on the EBITDA margin.
Q: Can you provide reassurance on new order trends, given concerns about sequential orders weakening? A: Florian Funck, CFO: We refrain from giving order intake numbers for individual quarters, but the 12-month rolling book-to-bill ratio is a better reflection. We are not aware of any pull-forward trends in Q1 or Q2. Michael Grosse, CEO: We have strong confidence in our overall guidance, with potential upside opportunities on the Bioprocess Solutions (BPS) side, while Lab Products & Services (LPS) remains more challenging.
